Is Revolution Medicines, Inc. (RVMD) a Buy, Sell, or Hold?
NASDAQ : RVMD
Revolution Medicines, Inc.
$189.23 USD
$0.48 (0.25%)
- Volume
- 1.29M
- Average Volume
- 2.84M
- Market Capitalization
- $40.23B
- P/E Ratio
- -26.61
- Dividend Yield
- 0.00%
- Price Target
- $195.00
- Year High
- $193.83
- Year Low
- $34.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.80
Company Overview
NASDAQ
Mark A. Goldsmith
Biotechnology
Healthcare
RVMD
883
US
USD
Liquidity Metrics
0.29
6.80
6.80
1.52
0.00
Sales & Valuation
-$
0.00
24.99
-37.54
-5.41
Profitability
-$5.95
-$1.13B
0.00%
0.00%
-83.22%
-60.86%
P/E Metrics
-26.61
0.54
0.54
Analyst Price Target & Rating
$195.00
$235.00
$144.00
1/5
23 Analysts
-2.96%
Financial Health Scores
28.89
1/9
$1.68B
$2.25B
$753.82M
-$1.34B
Key Metrics (TTM)
$40.23B
0.00
-30.50
6.80
-83.22%
-70.02%
-3.66%
-2.66%
-3182 days
Company Executives
| Name | Title |
|---|---|
| Stephen Kelsey Path. FRCP | Senior Advisor |
| Erin Graves | Senior Director of Corporate Communications & Investor Relations |
| Jack Anders | Chief Financial Officer |
| Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board |
| Mark A. Goldsmith | Chief Executive Officer, President & Chairman |
| Kevan Shokat | Academic Co-Founder & Member of Scientific Advisory Board |
| Michael A. Fischbach | Academic Co-Founder & Member of Scientific Advisory Board |
| Jan Smith | Chief Scientific Officer |
| Walter Reiher | Chief Information Officer |
| Margaret A. Horn | Chief Operating Officer |
| Jeff Cislini | Senior Vice President, General Counsel & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Revolution Medicines, Inc. (NASDAQ:RVMD) Stock
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG ... 12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
2026-07-23 14:11:06
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
2026-07-22 16:05:00
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company's New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
Revolution Medicines, Inc. $RVMD Shares Sold by California Public Employees Retirement System
2026-07-22 03:51:17
California Public Employees Retirement System trimmed its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 3.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 281,960 shares of the company's stock after selling 9,046 shares during the quarter. California Public Employees Retirement
Bessemer Group Inc. Sells 69,600 Shares of Revolution Medicines, Inc. $RVMD
2026-07-21 03:53:45
Bessemer Group Inc. reduced its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 59.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,062 shares of the company's stock after selling 69,600 shares during the period. Bessemer Group Inc.'s
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It
2026-07-17 08:30:00
Revolution Medicines aims to replace chemotherapy with target treatments. Its positive Phase 3 findings could pave the way towards its regulatory approval.
5 Stock Setups Where Wall Street Sees the Most Upside Right Now
2026-07-12 22:44:47
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now
Better Growth Buy: Axsome vs Revolution Medicines
2026-07-09 03:55:00
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
2026-07-07 09:23:00
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxonrasib, the company's investigational RAS(ON) multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.
Frequently Asked Questions
-
What is the current Revolution Medicines, Inc. (RVMD) stock price?
-
Revolution Medicines, Inc.(NASDAQ:RVMD) stock price is $189.23 in the last trading session. During the trading session, RVMD stock reached the peak price of $193.825 while $34 was the lowest point it dropped to. The percentage change in RVMD stock occurred in the recent session was 0.25% while the dollar amount for the price change in RVMD stock was $0.48.
-
RVMD's industry and sector of operation?
-
The NASDAQ listed RVMD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RVMD?
-
Stephen Kelsey Path. FRCP | Senior Advisor
Erin Graves | Senior Director of Corporate Communications & Investor Relations
Jack Anders | Chief Financial Officer
Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board
Mark A. Goldsmith | Chief Executive Officer, President & Chairman -
How many employees does RVMD have?
-
Number of RVMD employees currently stands at 883. RVMD operates from 700 Saginaw Drive, Redwood City, CA 94063, US.
-
Link for RVMD official website?
-
Official Website of RVMD is: https://www.revmed.com
-
How do I contact RVMD?
-
RVMD could be contacted at phone #650 481 6801 and can also be accessed through its website. RVMD operates from 700 Saginaw Drive, Redwood City, CA 94063, US.
-
How many shares of RVMD are traded daily?
-
The average number of RVMD shares traded daily for last 3 months was 2.84M.
-
What is the market cap of RVMD currently?
-
The market value of RVMD currently stands at $40.23B with its latest stock price at $189.23